Antares Pharma (NASDAQ:ATRS) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01, Morningstar.com reports. The company had revenue of $14.00 million for the quarter, compared to the consensus estimate of $15.44 million. Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year.
Shares of Antares Pharma (NASDAQ:ATRS) opened at $2.78 on Tuesday. The company has a market cap of $437.12, a PE ratio of -25.27 and a beta of 0.23. Antares Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $4.09. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69.
A number of equities analysts recently weighed in on the stock. ValuEngine raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Antares Pharma in a report on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. Antares Pharma presently has a consensus rating of “Buy” and an average price target of $3.94.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/13/antares-pharma-atrs-posts-earnings-results-beats-estimates-by-0-01-eps.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.